FDA adds heartburn drug being tested to treat COVID-19 to shortage list

The FDA added famotidine, a generic heartburn drug being tested to treat COVID-19, to its drug shortages list, Bloomberg reported. 

Researchers at Northwell Health in New Hyde Park, N.Y., are testing famotidine in high intravenous doses as a potential COVID-19 treatment. 

Shortly after the hospital announced the clinical trial, Amazon, Walgreens and CVS all reported shortages of the drug, sold under the brand name Pepcid. 

Teva Pharmaceutical, Carlsbad Technology and Aurobindo Pharma have all reported increased demand for famotidine, according to Bloomberg

The shortage comes just over a month after the FDA asked drugmakers to pull supplies of another common heartburn drug, ranitidine, off shelves after finding it contained unacceptably high levels of a carcinogen. 

Read the full article here.

More articles on pharmacy:
FDA clarifies relaxed compounding rules for pharmacies
Gilead gets FDA emergency use authorization for remdesivir
AmerisourceBergen offers to buy Walgreens' drug wholesaling division

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers